CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure p

Size: px
Start display at page:

Download "CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure p"

Transcription

1 CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure parameters during the diet and lifestyle improvement period before an eventual prescription of an antihypertensive treatment Anti-Hypertension Salt

2 Making the Earth Safe and Mankind Healthy ECHO BUSINESS PARTNER OBJECTIVES

3 POPULATION Patients characteristics' at inclusion visit Patients' demographic characteristics Age MV Anova: p-value: Sex % 66.7% % 33.3% Khi²: p-value:

4 Making the Earth Safe and Mankind Healthy ECHO BUSINESS PARTNER BMI MV Anova: 3.59 p-value: = 79.5 ± 22.2 Kg = 69.6 ± 14.3 Kg = ± 9.9 cm = ± 7.6 cm = 92.9 ± 16.3 cm = 89.1 ± 14.2 cm = 99.2 ± 9.4 cm = 96.6 ± 9.2 cm Anova: p-value: Anova: p-value: Anova: p-value: Anova: p-value: Cardiovalscular context % 33.3% 33.3% 25. Ficher: p-value: % 2 5.6% % 95. Ficher: p-value: Tabagism Diabete

5 Cardiovalscular context MV % 62.3% Ficher: p-value: Anova: p-value: % 21.1% 10.5% 11.1% 5.3% Dyslipidemia MV Anova: p-value: MV Anova: p-value: MV Anova: p-value:

6 Making the Earth Safe and Mankind Healthy ECHO BUSINESS PARTNER Patients evolution during first period (-) 90 A(n=18) B(n=20) ± ± 21.6 (w0-w8)=0.3 ± 2.3 p= p= Anova p= ± ± 14.1 (w0-w8)=-0.3 ± Blood pressure parameters evolution between and 160 A(n=18) B(n=20) ± ± ± 7.4 (w0-w8)=-6.2 ± ± 9.7 (w0-w8)=-13.2 ± p= p= Anova p=

7 100 A(n=18) B(n=20) ± ± ± 7.6 (w0-w8)=-6.1 ± p= ± 7.8 (w0-w8)=-11.4 ± 7.6 p= Anova p= Khi²: p-value: Khi²: p-value: % % A(n=18) SBP<140mmHg SBP<140mmHg and DBP<90mmHg B(n=20) 90 A(n=18) B(n=19) ± ± ± 9.2 (w0-w8)=0.1 ± ± 8.6 (w0-w8)=-1.3 ± p= p= Anova p=0.5014

8 Making the Earth Safe and Mankind Healthy ECHO BUSINESS PARTNER Biologics parameters evolution between and : blood ionogram 160 A(n=18) B(n=19) ± ± ± 1.8 (w0-w8)=0.3 ± ± 1.4 (w0-w8)=0.3 ± p= p= Anova p= A(n=17) B(n=19) ± ± ± 0.4 (w0-w8)=0.2 ± ± 0.3 (w0-w8)=-0.1 ± p= p= Anova p= A(n=16) B(n=18) ± ± ± 2.3 (w0-w8)=-0.8 ± ± 3.0 (w0-w8)=-0.6 ± p= p= Anova p=0.6726

9 35 A(n=11) B(n=14) ± ± ± 2.9 (w0-w8)=0.6 ± ± 2.0 (w0-w8)=0.8 ± p= p= Anova p= A(n=15) B(n=18) ± ± ± 0.8 (w0-w8)=-0.1 ± ± 1.4 (w0-w8)=-0.5 ± p= p= Anova p= Biologics parameters evolution between and : urinary ionogram ± ± 49.9 p= ± 93.2 (w0-w8)=33.6 ± ± 69.9 (w0-w8)=24.8 ± 69.3 p= Anova p= A(n=14) B(n=18)

10 Making the Earth Safe and Mankind Healthy ECHO BUSINESS PARTNER Biologics parameters evolution between and : blood ionogram 80 A(n=14) B(n=18) ± ± ± 33.2 (w0-w8)=5.7 ± ± 34.7 (w0-w8)=6.0 ± p= p= Anova p= ± ± 45.1 p= p= ± 86.3 (w0-w8)=45.8 ± ± 59.9 (w0-w8)=45.8 ± 50.6 Anova p= A(n=8) B(n=11) Any secondary effect was observed during first period MV Anova: p-value:

11 Crossover analysis A : -6.2 ± 7.3 B: ± 11.1 Anova p= B : -3.6 ± 8.4 A: 0.2 ± 8.2 Anova p= ± 4.7 p= A B t-test vs W ± 7.4 : p= ± ± 11.5 p= ± ± 9.7 Anova W10 p= Anova W18 p= ± ± 11.6 t-test vs W10 : p= w10 w18 B A A : -6.1 ± 7.1 B: ± 7.6 Anova p= B : -2.5 ± 6.0 A: -0.5 ± 5.1 Anova p= ± 3.5 p= A B t-test vs W ± 7.6 : p= ± ± 9.2 p= ± ± 7.8 Anova W10 p= Anova W18 p= ± ± 9.3 t-test vs W10 : p= B A w10 w18 The cross over analysis

12

<95DB8C9288E397C389C88A E696E6462>

<95DB8C9288E397C389C88A E696E6462> 2011 Vol.60 No.4 p.332 338 Usefulness of regional education program for dietary salt reduction: Self-monitoring of urinary salt excretion Kenichiro YASUTAKE[1] Kayoko SAWANO[1] Shoko YAMAGUCHI[1] Hiroko

More information

<82D282A982C1746F95F18D908F57967B95B E696E6464>

<82D282A982C1746F95F18D908F57967B95B E696E6464> 1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9

More information

180 140 22

180 140 22 21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3

More information

6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61

More information

Background : There have not been any informations available of whether diuretics may enhance renoprotective effects of ACEI and ARB. Methods Post-hoc analysis of the results of COOPERATE trial, asking

More information

2016.05月号cs5.indd

2016.05月号cs5.indd 5 2016.5.1 2 3 2016.5.1 2016.5.1 4 5 2016.5.1 2016.5.1 6 2016.5.1 7 2016.5.1 8 2016.5.1 9 2016.5.1 10 11 2016.5.1 2016.5.1 12 2016.5.1 13 Healthy 2016.5.1 14 2016.5.1 15 Healthy 2016.5.1 16 2016.5.1 17

More information

VOL.39 S-3

VOL.39 S-3 VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose

More information

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio 7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine

More information

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels

More information

JA2008

JA2008 A1 1 10 vs 3 2 1 3 2 0 3 2 10 2 0 0 2 1 0 3 A2 3 11 vs 0 4 4 0 0 0 0 0 3 6 0 1 4 x 11 A3 5 4 vs 5 6 5 1 0 0 3 0 4 6 0 0 1 0 4 5 A4 7 11 vs 2 8 8 2 0 0 0 0 2 7 2 7 0 2 x 11 A5 9 5 vs 3 10 9 4 0 1 0 0 5

More information

H O M E X 40th Period CSR Report 0 2 0 4 0 5 0 6 0 7 1 7 2 3 3 1 3 3 4 0 Contents 40th Period CSR Report 20131020149 Business partner Homate Cooperative Company Environment& Community 02 03 HONEST AND

More information

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date 1958-01 URL http://hdl.handle.net/2433/111559 Right Type Departmental Bulletin

More information

家庭系パソコンの回収再資源化にかかる論点

家庭系パソコンの回収再資源化にかかる論点 1 134 1212 134 2 1 137 1212 (1) 12 12,102 40.2 4,865 2-1 12 21,497 2-2 50.1 2-3 1 kg 2 12 2-1 13 12% 2-1 (2) 2-2 4 4 7 2-3 4 (3) 13.8 2-4 46 10 80 3 3 4 3 2-5, 2-6 13 9 2-7 18 2 2 8 5,000 30 25% 25 2 2

More information

Effects of a Mixing Tea Drink Containing Depolymerized. Sodium Alginate on Serum Total Cholesterol and Assessment of its Safety ABSTRACT A double blind placebo-controlled study was conducted in 100 subjects

More information

9 10 14 5 15 4 19 11 21 4 23 3 2012 24 11 24 5 24 6 27 2 447 52 395 27 2 1 2 3 4 5 6 7 8 9 10 11 12 (1) (2) (3) (4) 13 14 15 16 17 18 () 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40

More information

CHEMOTHERAPY Silver sulfadiazine (T 107) CHEMOTHERAPY Fig. 1 Item of patients Table 1 Criteria of bacteriological efficacy by the Committee xcellent: E Score of infection becomes to 0% at the end of medication.

More information

日本化学療法学会雑誌第66巻第2号

日本化学療法学会雑誌第66巻第2号 173 Table 1.Detection rates of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum, Haemophilus influenzae and adenovirus from male urethritis in Urethritis No.

More information

16 41 17 22 12 10

16 41 17 22 12 10 1914 11 1897 99 16 41 17 22 12 10 11 10 18 11 2618 12 22 28 15 1912 13 191516 2,930 1914 5,100 43 1.25 11 14 25 34364511 7.54 191420 434849 72 191536 1739 17 1918 1915 60 1913 70 10 10 10 99.5 1898 19034.17.6

More information

3.ごみの減量方法.PDF

3.ごみの減量方法.PDF - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - ( 100 ( 100 - 13-123,550,846 111,195,762 92,663,135 ( 12 25 37 49.2 16 33 49 65.6 15 30 44 59.0 2.5kg) ( 5kg) ( 7.5kg) ( k ( 123,550,846 111,195,762 92,663,135 (

More information

製品案内 価格表 2014/4/1

製品案内 価格表 2014/4/1 4 (17) 3 43 5/20370/ 231(504,150) 11 12 10 14-16 10 3 100 17 100kg 5-6 3 13 3 18 18 # # # # #$$ %&$ ' ()* +,-% ' #). +,-%'% / ' # # #$ %&&&'( %)* +'(#$ #$ %&&&'( ++,-). +'(#$ #$ /'( + /0)- +'(#$ %&&&'(

More information

180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3)

180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 12 12 72 (1) (2) (3) 12 (1) (2) (3) (1) (2) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (1) (2) 180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 30 16 (1) 31 (2) 31 (3) (1) (2) (3) (4) 30

More information

... 6

... 6 ... 6 1) 2) No. 01 02 03 04 05 06 07 08 09 10 11 12 No. 1 2 2 3 3cm 4

More information

untitled

untitled 1....1 2....2 2.1...2 2.2...2 3....14 3.1...14 3.2...14 4....15 4.1...15 4.2...18 4.3...21 4.4...23 4.5...26 5....27 5.1...27 5.2...35 5.3...54 5.4...64 5.5...75 6....79 6.1...79 6.2...85 6.3...94 6.4...

More information

113 120cm 1120cm 3 10cm 900 500+240 10 1 2 3 5 4 5 3 8 6 3 8 6 7 6 8 4 4 4 4 23 23 5 5 7

More information

untitled

untitled 21 14 487 2,322 2 7 48 4 15 ( 27) 14 3(1867) 3 () 1 2 3 ( 901923 ) 5 (1536) 3 4 5 6 7 8 ( ) () () 9 10 21 11 12 13 14 16 17 18 20 1 19 20 21 22 23 21 22 24 25 26 27 28 22 5 29 30cm 7.5m 1865 3 1820 5

More information

1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24

1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24 15 4 16 1988 63 28 19314 29 3 15 4 16 19283 15294 16 1930 113132 3 15 4 16 33 13 35 12 3 15 4 16 1945 10 10 10 10 40 1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11

More information

裁定審議会における裁定の概要 (平成23年度)

裁定審議会における裁定の概要 (平成23年度) 23 23 23 4 24 3 10 11 12 13 14 () 1 23 7 21 23 12 14 (19 ) 30 1.876% 60 8 24 19 78 27 1 (10) 37 (3) 2 22 9 21 23 5 9 21 12 1 22 2 27 89 10 11 6 A B 3 21 12 1 12 10 10 12 5 1 9 1 2 61 ( 21 10 1 11 30 )

More information

Microsoft Word - 入居のしおり.doc

Microsoft Word - 入居のしおり.doc 1 1 2 2 2 3 2 4 3 5 3 6 3 7 3 8 4 1 7 2 7 3 7 4 8 5 9 6 9 7 10 8 10 9 11 10 11 11 11 12 12 13 13 1 14 2 17 3 18 4 19 5 20 6 22 (1) 24 (2) 24 (3) 24 (4) 24 (5) 24 (6) 25 (7) 25 (8) 25 (9) 25 1 29 (1) 29

More information

和県監査H15港湾.PDF

和県監査H15港湾.PDF ...1...1...1...1...1...1...1...1...2...2...2...3...3...3...5...5...10...11...12...13...13...13...14...14...14...14...14...14...15...15...15...15...15 ...16...17 14...17...18...18...19...21...23 2...25...27...27...28...28...28

More information

2002 (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (6) (7) (8) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (8) No 2,500 3 200 200 200 200 200 50 200 No, 3 1 2 00 No 2,500 200 7 2,000 7

More information

-1- 4 1 2 4-2- -- 2 2 cm 0 80cm 2 80cm 80cm 80cm 50cm 80cm 50cm 6 80cm 100 50 50 cm 10 6 4 50cm 4 4 50cm -4- -5- cm 50cm 4 4 4 50cm 50cm 4 80cm 50cm 80cm 50cm 6 cm -6- 20 250cm 1 2 1 4 0cm 60cm cm cm 1

More information

河川砂防技術基準・基本計画編.PDF

河川砂防技術基準・基本計画編.PDF 4 1 1 1 1 1 2 1 2.1 1 2.2 2 2.3 2 2.4 2 3 2 4 3 2 4 1 4 1.1 4 1.2 4 2 4 2.1 4 2.2 4 2.3 5 2.4 5 2.5 5 2.5.1 5 2.5.2 5 2.6 5 2.6.1 5 2.6.2 5 2.6.3 5 2.6.4 5 2.6.5 6 2.7 6 2.7.1 6 2.7.2 6 2.7.3 6 2.7.4

More information

4 100g

4 100g 100g 10 20 30 40 50 60 70 80 4 5 7 9 12 15 19 24 60 100 10 80 100 20 10 5 20 195 20-1- 60 60 15 100 60 100 15 15 15 100 15 15 60 100 10 60 100 100 15 10 10 60 100 15 10 15 10 5-2- 80 80 24 100 80 100 24

More information

( )

( ) ( ) () () 3 cm cm cm cm cm cm 1000 1500 50 500 1000 1000 1500 1000 10 50 300 1000 2000 1000 1500 50 10 1000 2000 300 50 1000 2000 1000 1500 50 10 1000 2000 300 30 10 300 1000 2000 1000 1500 1000

More information

-26-

-26- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- cm -39- -40- 1 2 3 4 4 3 2 1 5 5-41- -42- -43- -44- -45- -46- -47- -48- -49- -50- cm -51- -52- -53- -54- -55- -56- -57- -58- -59- -60-

More information

untitled

untitled () () () () () ( ) () ( ) () ( ) () 2 () () 2 () () ( ) () () () 2 () () 2 3 ( ) () ( ) 2 3 4 () () 2 3 4 () () ( )( ) ( ) 2 ( ) 3 () () 2 3 () () 2 3 () () () () () () () () (( ) ( ) (( ))( )( ) ) 2 3

More information

untitled

untitled 146,650 168,577 116,665 122,915 22,420 23,100 7,564 22,562 140,317 166,252 133,581 158,677 186 376 204 257 5,594 6,167 750 775 6,333 2,325 298 88 5,358 756 1,273 1,657 - - 23,905 23,923 1,749 489 1,309

More information

2009年133巻3号3月号.indb

2009年133巻3号3月号.indb Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine

More information

CHEMOTHERAPY SEPT. 1991

CHEMOTHERAPY SEPT. 1991 CHEMOTHERAPY SEPT. 1991 VOL. 39 S-3 Table 1. Background of characteristics and allocation of 9 healthy male volunteers in a single-dose study on betamipron Table 2. Background of characteristics and allocation

More information

388599-P036-P041

388599-P036-P041 Die life improvement of flat type punches for hot forging Morihiko Nakasaki, Koji Era, Hiroyuki Myochin and Ichiro Takasu Synopsis: Since forged products have been required more complex and net-shape,

More information

VOL.42 S-1

VOL.42 S-1 CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical

More information

!!! 10 1 110 88 7 9 91 79 81 82 87 6 5 90 83 75 77 12 80 8 11 89 84 76 78 85 86 4 2 32 64 10 44 13 17 94 34 33 107 96 14 105 16 97 99 100 106 103 98 63 at 29, 66 at 58 12 16 17 25 56

More information

Effects of Diet Class on Overweight Middle-aged Women Analysis of Nutritional Intake Pattern YAMAGUCHI Shizue*, MATSUMOTO Tomoko**, MIMURA Kan-ichi***, ASAI Hitoshi****, OKUDA Toyoko***** * O saka Shin-ai

More information

[] 1

[] 1 0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2

More information

...S.....\1_4.ai

...S.....\1_4.ai * ** *** * ** *** 20 17 BMI 10 20 10 20 96 2000 2000a 2000b 2005 2004 binge eating 1997 2003 2004 2000 2000b 10 20 30 BMI 2000a BMI 2005 2004 97 2003 2003 2006 2003 2003 1997 binge eating binge eating

More information

緑化計画作成の手引き 26年4月版

緑化計画作成の手引き  26年4月版 http://www.city.shibuya.tokyo.jp/env/en_eventact/midori_ryokka.html 10 11 12 13 14 15 16 17 18 19 P10 P10 1 P12 2635 Fax (1) 47 03-5388-3554 http://www2.kankyo.metro.tokyo.jp/sizen/sinseisyo/e2/tebiki.htm

More information

便失禁に対する仙骨神経刺激療法 前向き多施設共同研究 第67巻06号0371頁

便失禁に対する仙骨神経刺激療法 前向き多施設共同研究 第67巻06号0371頁 67 I 1 2 3 日本大腸肛門病会誌 年間 1-1 号 第 67 巻第 6 号 (%) 1 214 年 6 月 山名哲郎ほか 375 (%) 1 8 8 5. 66.7 6 66.7 66.7 4 6 4 56.3 56.3 18.8 6.3 18.8 23.8 4.5 Test period 4.8 1M 3M 6M Test period 1M 3M 6M (n = 22) (n = 16)

More information

日本消化器外科学会雑誌第30巻第3号

日本消化器外科学会雑誌第30巻第3号 Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment

More information

untitled

untitled 1988 2000 2002 2004 2006 2008 IFN Lamivudine Adefovir Entecavir 1 Total number 560 Sex (male/female) 424/136 Age (years)* 38 (15-68) Duration of treatment (weeks)* 26 (1-592) Follow-up time (years) 75(05-21

More information

32-1_会告.indd

32-1_会告.indd 原 著 Relationship between Urinary Incontinence and Childbirth Among Women who Have Given Birth within the Last Three Years The Role of Midwives in the Prevention and Improvement of Urinary Incontinence

More information

.K.C.h...C...ren

.K.C.h...C...ren 4 quality of life QOL QOL QOL 3 QOL 19 mmhg 16 mmhg 14 mmhg 1 2 7 20 30 QOL QOL QOL QOL QOL QOL QOL 4 1 1 1 2 1 2 3 1 2 4 2 2 1 2 2 2 2 1 2 3 QOL 3 2 1 1 5 1 1 2 1 Abraham Wise 1 Nd YAG 2 1 200 500 200

More information

untitled

untitled 1 2 3 4 5 6 7 cm kg 8 9 10 11 12 13 14 15 T A S H A A M.. N.. A.. B.. I 16 17 18 C 19 20 holding 21 22 23 24 STEP1 STEP2 STEP3 STEP4 STEP5 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

More information

1) Richter, C. P.: Ann. Rev. Physiol., 4, 561 (1942) 2) A. L. Fox: Proc. Nat. Acad. Sci., Wash., 18, 115(1931) 4) Hansen, R. u. W. Langer: Klin. Wschr, 9) Katsch, G. u. H. Pickert: Handb. d. Inn. Med.

More information

Demography UN, World Population Prospects: 2000 n UN, World Population Prospects: P1P0 n UN, World Population Prospects: n P1P0 n UN, World Population Prospects: 2000

More information

( ) ( ) 87 ( ) 3 ( 150mg/l) cm cm 50cm a 2.0kg 2.0kg

( ) ( ) 87 ( ) 3 ( 150mg/l) cm cm 50cm a 2.0kg 2.0kg 8 12 8 16.2004 1 2 The Effect of Planting Time and Mulching on Chinese Cabbage which to be Harvested from January to February Hitoshi KIMURA,Makoto MIYAGI and Masahito SUZUKI Summary In the cultivation

More information

Vol. No. Honda, et al.,

Vol. No. Honda, et al., A Study of Effects of Foot Bath before Exercise on Fall Prevention Yoko Honda Yoko Aso Aki Ibe Megumi Katayama Tomoko Tamaru Key Words fall prevention, foot bath, elderly, fall prevention programs Honda,

More information

988 CHEMOTHERAPY NOV. 1971

988 CHEMOTHERAPY NOV. 1971 988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical

More information

日本化学療法学会雑誌第65巻第4号

日本化学療法学会雑誌第65巻第4号 Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae

More information

untitled

untitled 1 2 3 4 5 6 7 48.4 7 1 2 1210 2.5 10 15 37.5 6 8 2.5 10 3 25 19 2.5 15 3 55 37.5 4.5 10 5 25 19 4.5 15 5 55 19 4.5 15 5 92 37.5 1 4 550 3 2500 3 3 3 50 10 15 15 19 19 37.5 5 8 15 b 10 15 19 37.5

More information

<30388DE288E42E696E6464>

<30388DE288E42E696E6464> Doshisha Journal of Health & Sports Science, 1, 53-60, 2009 53 1 Effects of Step Exercise in Healthy Older People Tomoaki Sakai 1 The purpose of this study was to determine the effect of step exercise

More information

Arthroscopic Treatment for Painful Bennett Lesions of the Shoulder in Baseball Players by M. Yoneda and K. Hayashida Department of Orthopaedic Surgery

Arthroscopic Treatment for Painful Bennett Lesions of the Shoulder in Baseball Players by M. Yoneda and K. Hayashida Department of Orthopaedic Surgery Arthroscopic Treatment for Painful Bennett Lesions of the Shoulder in Baseball Players by M. Yoneda and K. Hayashida Department of Orthopaedic Surgery, Osaka Kosei-Nenkin Hospital K. Izawa and S. Wakitani

More information

164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10

164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10 163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination

More information

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic COMPARATIVE CLINICAL EFFECT OF AMIKACIN AND GENTAMICIN ON COMPLICATED URINARY TRACT INFECTIONS BY DOUBLE-BLIND METHOD Tsuneo Nishiura and Yukimichi Kawada Department of Urology, Gifu University School

More information

ON A FEW INFLUENCES OF THE DENTAL CARIES IN THE ELEMENTARY SCHOOL PUPIL BY Teruko KASAKURA, Naonobu IWAI, Sachio TAKADA Department of Hygiene, Nippon Dental College (Director: Prof. T. Niwa) The relationship

More information

..,,...,..,...,,.,....,,,.,.,,.,.,,,.,.,.,.,,.,,,.,,,,.,,, Becker., Becker,,,,,, Becker,.,,,,.,,.,.,,

..,,...,..,...,,.,....,,,.,.,,.,.,,,.,.,.,.,,.,,,.,,,,.,,, Becker., Becker,,,,,, Becker,.,,,,.,,.,.,, J. of Population Problems. pp.,,,.,.,,. Becker,,.,,.,,.,,.,,,,.,,,.....,,. ..,,...,..,...,,.,....,,,.,.,,.,.,,,.,.,.,.,,.,,,.,,,,.,,, Becker., Becker,,,,,, Becker,.,,,,.,,.,.,, ,,, Becker,,., Becker,

More information

1) Lysozyme and Viral Infections, 2nd Intern- Symposium on Fleming's Lysozyme, ational Milano, Apr. 1961. 2) Ermol'eva, Z.V. et al.: Experimental study and clinical application of lysozyme. Fed. Proc.

More information

untitled

untitled Bull. Shiga. Pref. Agric.Tech.Promo.Cent. 4645 55 2007 Improvement in Quality and Profitability in Tea Cultivation with Direct Covering Koji CHUTANI 10a 17 10 13 5 17 13 5 10a 10 5 3 5 1,2,3,8,12 1 6 39t

More information

07.報文_及川ら-二校目.indd

07.報文_及川ら-二校目.indd 8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006

More information

Corrosion Wear of Alloy Tool Steel (SKD 11) Coated with VC and Precipitation Hardening Stainless Steel (SUS 630) in Sodium Chloride Aqueous Solution T

Corrosion Wear of Alloy Tool Steel (SKD 11) Coated with VC and Precipitation Hardening Stainless Steel (SUS 630) in Sodium Chloride Aqueous Solution T Corrosion Wear of Alloy Tool Steel (SKD 11) Coated with VC and Precipitation Hardening Stainless Steel (SUS 630) in Sodium Chloride Aqueous Solution Toshiyuki TANAKI*, Makoto YUASA** and Isao SEKINE***

More information

日本化学療法学会雑誌第51巻第2号

日本化学療法学会雑誌第51巻第2号 piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC

More information

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii

More information

untitled

untitled Vol.4(2008) pp.41-52 1 1 2 3 1 1 1 2 3 19 12 20 Preliminary Studies of Robot Assisted Rehabilitation Using Commercially Available Entertainment Robots Toshihiro TETSUI 1 Eiichi OHKUBO 1 Noriko KATO 2 Shin

More information

Ⅱ. 研究目的 Ⅲ. 研究方法 1. 対象者 J.. 2. 用具.... Ledraplastic GYMNIC cm 3. 大型ボールを用いたトレーニング内容 DVD DVD

Ⅱ. 研究目的 Ⅲ. 研究方法 1. 対象者 J.. 2. 用具.... Ledraplastic GYMNIC cm 3. 大型ボールを用いたトレーニング内容 DVD DVD 研究ノート 大型ボールの身体的効果に関する研究 平衡性機能と姿勢保持のトレーニング効果に着目して Study of Effect of Large-sized ball on Human Body Shedding light on the effect of training on balance function and posture retention Yoshika MarikoYoshinori

More information

Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST

Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.

More information

居眠り事故を未然に防止するための睡眠・覚醒管理技術の開発

居眠り事故を未然に防止するための睡眠・覚醒管理技術の開発 30 1520 12) 3) 31 4) 10151 23 15 20 3 16 11,400,000 0 11,400,000 17 1,500,000 0 1,500,000 18 1,500,000 0 1,500,000 19 1,600,000 480,000 2,080,000 16,000,000 480,000 16,480,000 1 5 11 1 11 2 23 3 39 1 43

More information

Experimental and Clinical Studies of Pregnant Hypertension Takashi SHIMAZU Department of Obstetrics and Gynecology, Osaka City University Medical Scho

Experimental and Clinical Studies of Pregnant Hypertension Takashi SHIMAZU Department of Obstetrics and Gynecology, Osaka City University Medical Scho Experimental and Clinical Studies of Pregnant Hypertension Takashi SHIMAZU Department of Obstetrics and Gynecology, Osaka City University Medical School While the problem of late pregnant hypertension

More information

社会学部紀要 119号☆/表紙(119)

社会学部紀要 119号☆/表紙(119) October 2014 2 2014 SSM SSM 1 1 1.1 1909 2002 2002 : 114 1965 SSM 20101965 40 1917 26 50 1907 1916 1917 26 1907 16 SSM 1 1 1886 1896 1906 1916 1926 95 05 15 25 35 31.6 47.4 10.5 5.3 5.3 32.4 51.4 13.5

More information